LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
January 05, 2024 17:45 ET
|
LumiraDx Inc
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its...
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
December 29, 2023 16:15 ET
|
LumiraDx Inc
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint...
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
October 27, 2023 16:45 ET
|
LumiraDx Inc
LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of...
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
October 20, 2023 18:34 ET
|
LumiraDx Inc
Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club – Everton in the Community – the Liverpool-based hub will provide...
LumiraDx Reports Second Quarter 2023 Results
August 24, 2023 07:45 ET
|
LumiraDx Inc
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended...
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
August 16, 2023 16:30 ET
|
LumiraDx Inc
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results...
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
July 31, 2023 06:00 ET
|
LumiraDx Inc
Partnership between LumiraDx and Axonlab will allow Axonlab to sell the unique LumiraDx Point of Care testing solution and give LumiraDx the ability to expand the reach of the LumiraDx Platform and...
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
June 30, 2023 14:30 ET
|
LumiraDx Inc
LONDON, June 30, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading innovator in diagnostic technologies, today announced the submission of its first 510(k) application to the U.S....
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
June 20, 2023 16:15 ET
|
LumiraDx Inc
LumiraDx SARS-CoV-2 Ag Ultra & SARS-CoV-2 Ag & RSV tests have been successfully validated by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Coronavirus Test Device...
LumiraDx Reports First Quarter 2023 Results
May 16, 2023 07:45 ET
|
LumiraDx Inc
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended...